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A B S T R A C T
Duchenne and Becker muscular dystrophies are X-linked hereditary myopathies secondary to a
dystrophinopathy resulting in progressive cardiomyopathy and heart failure. The most commonly
associated cardiac involvements in these patients are dilated cardiomyopathy and conduction
abnormalities; however, recent studies have shown a high prevalence of left ventricular noncompaction
cardiomyopathy in patients with Duchenne muscular dystrophy. Furthermore, there is increasing
awareness of cardiomyopathy in female heterozygous dystrophinopathy carriers. We report a case series
of two dystrophinopathy carriers with the dilated form of left ventricular noncompaction
cardiomyopathy, a newly identiﬁed association.
<Learning objective: Dystrophinopathy carriers can manifest cardiac disease in the form of
cardiomyopathy. We present a novel ﬁnding of carriers who manifest their cardiomyopathy in the
form of left ventricular noncompaction, dilated phenotype. This has been described previously in
patients with Duchenne muscular dystrophy.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Duchenne (DMD) and Becker (BMD) muscular dystrophies are
X-linked hereditary myopathies stemming from mutations in the
dystrophin gene and result in inexorably progressive cardiomyop-
athy. Dilated cardiomyopathy and conduction abnormalities are
the hallmark of cardiac involvement in this disease process;
however, recent studies have shown a high prevalence of left
ventricular noncompaction cardiomyopathy (LVNC) in patients
with DMD as well [1,2].
Female heterozygous dystrophinopathy carriers are known to
be at risk for the development of cardiomyopathy, and thus
ongoing surveillance in these patients is warranted [3]. In fact, the
American Academy of Pediatrics issued recommendations in
2005 on the appropriate approach to female carriers including:
education regarding the risk, complete evaluation in late adoles-
cence or early adulthood, and reevaluation at least every 5 years
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LVNC, a newly identiﬁed association. The aim of this case series is
to heighten the awareness of LVNC in dystrophinopathy carriers, as
this diagnosis may be missed. Additionally LVNC is a distinct
cardiomyopathy and its diagnosis should lead to unique surveil-
lance and treatment strategies in affected patients.
Case reports
Patient 1
Patient 1 is a 57-year-old female with duplication of exons
46–48 of the dystrophin gene. She underwent cardiac testing after
knowledge of her carrier status. Holter monitor showed rare
premature ventricular contractions (PVCs) and a single 6-beat
episode of nonsustained ventricular tachycardia. Electrocardio-
gram was normal, with sinus rhythm at 60 beats per minute.
Cardiac magnetic resonance imaging (CMR) revealed a mildly
dilated left ventricle with mildly reduced left ventricular systolic
function (ejection fraction 48%) as well as LVNC (Fig. 1, Videos
1 and 2). Additionally, late gadolinium enhancement was noted in
basal inferolateral and anterolateral segments, and the mid
ventricle inferior, inferolateral, and anterolateral and apical
anterior and lateral segments. reserved.
Fig. 1.
Patient 1: cardiac magnetic resonance (CMR) left ventricular noncompaction images. Patient 1 had a CMR that demonstrated prominent trabeculations seen in
the midventricular and apical portion of the left ventricle with a noncompacted to compacted ratio of 2.4:1 in end-diastole. (Left) Short-axis bright blood still
image. (Right) Four-chamber bright blood still image.
Fig. 2.
Patient 2: cardiac magnetic resonance late gadolinium enhancement
imaging. Short-axis image of cardiac magnetic resonance showing a
thinned appearance of the midventricular inferolateral region with
late-gadolinium enhancement (arrow).
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with spironolactone, losartan, and extended-release metoprolol.
Low-dose aspirin was also initiated secondary to diminished left
ventricular function in the setting of LVNC that poses a
thromboembolic risk. Repeat evaluation has shown stable
magnetic resonance imaging and electrocardiographic ﬁndings.
She remains asymptomatic and will continue to be monitored
annually at this point.
Patient 2
Patient 2 is a 33-year-old woman who had three sons affected
by DMD and was found herself to have a point mutation in exon
34 of the DMD gene (c.4843A>T mutation), identical to her
affected sons. She was referred for consultation in the DMD/BMD
carrier clinic at our institution. She had been asymptomatic from a
cardiac standpoint.
Initial cardiac work-up included a Holter monitor which
showed rare PVCs and ventricular couplets, as well as rare
premature atrial contractions (PACs). Electrocardiogram demon-
strated normal sinus rhythm at 62 beats per minute and T-wave
inversion in the inferior leads. CMR revealed a mildly dilated left
ventricle with mildly reduced left ventricular ejection fraction
(49%). The CMR also showed a segmental wall motion abnormality:
hypokinesis of the mid and basal inferolateral segments with
partial thickness epicardial late gadolinium enhancement in the
same regions (Fig. 2). There were also prominent trabeculations inFig. 3.
Patient 2: cardiac magnetic resonance (CMR) left ventricular noncompaction im
left ventricular apex and extending along the lateral free wall to the midventri
Short-axis bright blood still image. (Right) Four-chamber bright blood still ithe left ventricular apex and extending along the free wall to the
midventricular level, consistent with LVNC (Fig. 3, Videos 3 and 4).
Given the above ﬁndings, the treatment of the patient was
started with carvedilol and lisinopril. Low-dose aspirin was alsoages. Patient 2 had a CMR that demonstrated prominent trabeculations within the
cular level with a noncompacted to compacted ratio of 2.3:1 in end-diastole. (Left)
mage.
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up (1 year following diagnosis) she has remained asymptomatic. A
recent echocardiogram showed persistence of a mildly dilated left
ventricle but normalization of her left ventricular function. She has
not been restricted from activities and will have ongoing
monitoring with serial imaging (echocardiography or CMR),
electrocardiograms, and Holter monitors.
Discussion
LVNC is a unique cardiomyopathy characterized by a com-
pacted thin layer underlying a much thicker noncompacted
endocardial layer of deep trabeculae. Several proposed diagnostic
imaging criteria have been proposed for LVNC and they vary
slightly among authors as well as by imaging modality (echocar-
diogram versus CMR). The patients above met the CMR criteria for
LVNC set forth by Petersen et al. with a noncompacted to
compacted ratio of >2.3/1 in end-diastole [5].
Dystrophin is the protein found in the cardiac myocyte that
anchors the cytoskeleton to the extracellular matrix. Given the role
of the extracellular matrix in the developing heart, including the
compaction process in early fetal development, one can theorize
that dystrophinopathies could result in abnormalities in compac-
tion, thus resulting in left ventricular noncompaction cardiomy-
opathy [6].
Interestingly, patient 1 had one son with DMD and he had no
cardiac involvement, including no evidence of LVNC at age 18 years
by CMR. Similarly, patient 2 had three sons with DMD (ages 3, 5,
and 9 years), all without cardiac involvement to date, including
absence of LVNC (by echocardiogram only in the younger two sons
and CMR in the oldest). It is known that many modiﬁers can play a
role in how and when a cardiomyopathy develops, even among
family members with the same gene defect. This could explain the
phenotypic variation in our cases between affected sons and
carrier mothers. However, it is possible that the carrier mothers
harbor a sarcomeric gene defect that was not tested.
Regardless, the diagnosis of LVNC is important to make for
reasons stated below. LVNC is associated with a variety of
myocardial phenotypes including: dilated, hypertrophy, mixed
(dilated and hypertrophied), restrictive, or normal cardiac dimen-
sions and wall thickness. Some have reported LVNC as an acquired
or even secondary compensatory process; however, the authors of
this report strongly believe LVNC to be a primary phenotype that
can result in progressive cardiac dysfunction and/or be associated
with dysrhythmias or thromboembolic events. Awareness of the
natural history and risks associated with LVNC is crucial for patient
surveillance and management as it can reduce morbidity and
mortality [7]. Once LNVC is diagnosed, independent of cardiac
function, we believe that this should increase imaging and
dysrhythmia surveillance as well as be a pause for anticoagulationconsiderations, as LVNC places patients at a higher risk for
thromboembolic events. Such a strategy may result in early
treatment and better outcomes.
Conclusions
We believe that this report illustrates the ﬁrst case series of
coincident LVNC (dilated phenotype) in dystrophinopathy carriers.
Physicians should continue to recommend serial cardiac evalua-
tions in carriers because of the increased prevalence of cardiomy-
opathy, which may include LVNC, in this population. Heightened
awareness of LVNC in such carriers may further improve diagnostic
accuracy and care in these patients and will likely alter treatment
and surveillance once identiﬁed. Further studies should aim to
characterize cardiomyopathies in DMD and BMD carriers more
fully. LVNC may be more prominent in dystrophinopathy carriers
than previously understood, just as recent studies have shown it to
be in male DMD patients.
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